纳武利尤单抗联合低剂量伊匹木单抗治疗既往经治的微卫星高度不稳定/错配修复缺陷转移性结直肠癌:CheckMate 142研究4年随访
CheckMate 142研究II期多队列部分,既往经治的MSI-H/dMMR转移性结直肠癌患者接受纳武利尤单抗联合低剂量伊匹木单抗治疗,中位随访50.9个月时研究者评估的客观缓解率从13.4个月时的55%升至65%,完全缓解率从3%升至13%,安全性可控,未观察到新的安全信号。
要点
- 中位随访50.9个月时研究者评估的ORR为65%(95%CI 55%-73%),疾病控制率为81%(95%CI 72%-87%)。
- 完全缓解率从13.4个月时的3%升至50.9个月时的13%,中位缓解持续时间未达到。
- 3-4级治疗相关不良事件发生率为32%,13%的患者因任何级别治疗相关不良事件停药。
核心结论
- 结果证实纳武利尤单抗联合低剂量伊匹木单抗对既往经治的MSI-H/dMMR转移性结直肠癌患者具有长期获益,安全性可控且未观察到新的安全信号。
研究设计与样本
- II期多队列CheckMate 142研究,共119例既往经治的MSI-H/dMMR转移性结直肠癌患者接受治疗,76%的患者接受过≥2线既往治疗。
- 患者接受纳武利尤单抗(3 mg/kg)联合低剂量伊匹木单抗(1 mg/kg)每3周一次共4次,随后纳武利尤单抗(3 mg/kg)每2周一次直至疾病进展。
- 主要终点为研究者评估的客观缓解率(按RECIST版本1.1)。
- 中位随访时间为50.9个月(范围46.9-62.7个月),中位治疗持续时间为24.9个月(95%CI 15.8-33.2个月)。
主要发现
- 研究者评估的ORR从13.4个月时的55%(95%CI 45%-64%)升至50.9个月时的65%(95%CI 55%-73%),疾病控制率为81%(95%CI 72%-87%)。
- 完全缓解率从13.4个月时的3%升至50.9个月时的13%;部分缓解见于52%的患者,21%的患者疾病稳定,12%的患者疾病进展。
- 中位起效时间为2.8个月(范围1.1-37.1个月),中位缓解持续时间未达到(范围1.4+至58.0+个月),数据截止时37例(48%)患者缓解持续。
- 中位无进展生存期未达到(95%CI 38.4个月-不可估计),中位总生存期未达到(95%CI 不可估计)。
- 3-4级治疗相关不良事件发生于32%的患者,13%的患者因任何级别治疗相关不良事件导致停药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase II multicohort CheckMate 142 study, nivolumab plus low-dose (1 mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable safety profile in previously treated patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) at 13.4- and 25.4-month median follow-up (Overman MJ, Lonardi S, Wong KYM et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773-779. Overman MJ, Lonardi S, Wong KYM, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: long-term follow-up. J Clin Oncol. 2019;37:635). Here, we present results from the 4-year follow-up of these patients. PATIENTS AND METHODS: Patients received nivolumab (3 mg/kg) plus low-dose (1 mg/kg) ipilimumab every 3 weeks (four doses) followed by nivolumab (3 mg/kg) every 2 weeks until disease progression. Primary endpoint was investigator-assessed objective response rate (ORR; as per RECIST version 1.1). RESULTS: A total of 119 patients were treated; 76% had ≥2 prior lines of therapy. Median follow-up was 50.9 months (range 46.9-62.7 months). Median duration of therapy was 24.9 months [95% confidence interval (CI) 15.8-33.2 months]. Investigator-assessed ORR increased from 55% (95% CI 45% to 64%) at 13.4 months to 65% (95% CI 55% to 73%) at 50.9 months with a disease control rate of 81% (95% CI 72% to 87%). The complete response rate increased from 3% at 13.4 months to 13% at 50.9 months. Partial responses were observed in 52% of patients; 21% had stable disease, and 12% had progressive disease. Median time to response was 2.8 months (range 1.1-37.1 months), and median duration of response was not reached (range 1.4+ to 58.0+ months). At data cut-off, 37 (48%) patients had ongoing responses. Median progression-free survival was not reached [95% CI 38.4 months-not estimable (NE)], and median overall survival was not reached (95% CI NE). Grade 3-4 treatment-related adverse events (TRAEs) were observed in 32% of patients; 13% of patients had any-grade TRAEs leading to discontinuation. CONCLUSIONS: The results confirm long-term benefit of nivolumab plus low-dose ipilimumab for previously treated patients with MSI-H/dMMR mCRC. The safety profile was manageable with no new safety signals.
引用
- André T, Lonardi S, Wong KYM, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022. PMID: 35764271. doi:10.1016/j.annonc.2022.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。